Avomeen Analytical Services, Inc

Avomeen Analytical Services, Inc is a specialized laboratory providing comprehensive testing and analysis services across several sectors including pharmaceuticals and environmental services, ensuring product safety and compliance with regulatory standards. Avomeen Analytical Services, Inc was founded in 2010 in Ann Arbor, US. The company operates as an independent entity without known subsidiaries. The firm was established to provide tailored analytical services and has completed a total of 2 deals, with the most recent deal occurring on February 3, 2021.

The current CEO is Mark Harvill, and the founder is Shri Thanedar, who has a history of entrepreneurial ventures. Avomeen Analytical Services' Life Sciences division focuses on a comprehensive suite of testing and laboratory services tailored for various sectors including Pharmaceuticals, Medical Devices, Biotech, Antimicrobial, Food, and Environmental testing. Their core offerings encompass chemical characterization, microbiological analysis, stability testing, and environmental assessments, designed to ensure product safety and compliance with stringent regulatory requirements. These services cater to a diverse client base, including manufacturers, R&D organizations, and regulatory agencies, facilitating the development and market approval of innovative products.

Avomeen operates in key geographical markets, including North America, Europe, and Asia, providing high-quality testing solutions that meet local and international standards. Avomeen's revenue model is based on B2B transactions involving clients from large pharmaceutical corporations to smaller biotech firms. The company structures its transactions around tailored service agreements, often built around project-based contracts or ongoing partnerships that provide clients with continuous testing solutions. Pricing is determined by the complexity and scope of services rendered, with flagship offerings such as comprehensive safety testing packages and specialized antimicrobial assessments establishing the baseline for service costs.

These agreements are vital for compliance and product launch timelines, creating a steady revenue stream through repeated business engagements across multiple sectors. Following the acquisition of Avomeen Analytical Services, Inc by Element Materials Technology Group Limited, a portfolio company of Bridgepoint, in February 2021, the company aims to enhance its life sciences business unit in North America. Future growth strategies include launching new products and expanding into additional geographic markets, although specific details on product releases and targeted regions have not been disclosed. The acquisition will support these initiatives by leveraging Element's resources and expertise to strengthen Avomeen's market position.